Download highlights from our latest eBook when you complete the form below.
In this eBook, we explore the quality control guidelines for clinical-grade human iPSC lines and delve further into raw/ancillary material qualification for stem cell therapy manufacturing. We also take a look at the therapeutic potential of these cells, including the first trial of iPSCs for Parkinson's disease.
Contents include:
- [FOREWORD] Welcome to our eBook on iPSCs: from the bench to the clinic
- [INTERVIEW] Continuous innovation for manufacturing raw/ancillary materials at scale: an interview with Sean Kevlahan
- [OPINION ARTICLE] Raw/ancillary material qualification for stem cell therapy manufacturing
- [WHITE PAPER] Quality control guidelines for clinical-grade human induced pluripotent stem cell lines
- [INTERVIEW] Preparing for the first human trial of induced pluripotent stem cell-derived cells for Parkinson's disease: an interview with Jun Takahashi
- [INTERVIEW] The therapeutic potential of iPSCs: an interview with Ross Macdonald